Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Grants Fast Track To Eli Lilly And AstraZeneca’s Alzheimer’s Drug

XTALKS VITALS NEWS

The FDA’s fast track program helps accelerate the review of new drugs which have the potential to fill a gap in the therapeutic market.

Tweetables from this article:

Tweet: Eli Lilly and AstraZeneca's BACE inhibitor #Alzheimers drug is currently being assessed in Phase III #clinicaltrials http://ctt.ec/O910p+ Eli Lilly and AstraZeneca's BACE inhibitor Alzheimer's drug is currently being assessed in Phase III clinical trials.

Tweet: BACE inhibitor has shown promise in reducing amyloid beta levels in the cerebrospinal fluid of #Alzheimers patients http://ctt.ec/6KP42+ BACE inhibitor has shown promise in reducing amyloid beta levels in the cerebrospinal fluid of Alzheimer's patients.

Share this!

August 24, 2016 | by Sarah Massey, M.Sc.

A drug designed to treat patients in the early stages of Alzheimer’s disease has been granted a fast track designation by the US Food and Drug Administration (FDA). The drug – developed by Eli Lilly and AstraZeneca – is a beta secretase cleaving enzyme (BACE) inhibitor that is currently being assessed in Phase III clinical trials.

“We are pleased the FDA places a high priority on the development of drugs that target Alzheimer's disease, one of the most critical health issues of our time,” said Phyllis Ferrell, vice president and global development leader for Alzheimer's disease at Eli Lilly. “Most importantly, this is a positive step forward for the millions of patients, families, caregivers, advocates and healthcare providers who fight every day for progress.”

The FDA’s fast track program helps accelerate the review of new drugs which have the potential to fill a gap in the therapeutic market. The BACE inhibitor, AZD3293, has shown promise in reducing amyloid beta levels in the cerebrospinal fluid of healthy volunteers and Alzheimer’s patients.



As the accumulation of amyloid beta is a hallmark of Alzheimer’s pathology, AZD3293 is designed to reduce levels of an enzyme, BACE, which is involved in amyloid beta formation. A continuing Phase II/III clinical trial called AMARANTH is ongoing to test the efficacy of this BACE inhibitor.

“The Fast Track designation in the U.S. for this promising potential therapy reinforces the ambition of the AstraZeneca-Lilly BACE alliance to help advance science for patients and their families managing this devastating illness,” said Craig Shering, AZD3293 Project Lead in Global Medicines Development at AstraZeneca. “BACE inhibitors have the potential to transform the treatment of Alzheimer's disease, one of the biggest challenges facing medical science today.”

Eli Lilly and AstraZeneca have also announced that they plan to start an additional Phase III clinical trial for AZD3293. The DAYBREAK-ALZ study – which started to enroll participants earlier this year – will investigate the safety and efficacy of the BACE inhibitor in patients with mild Alzheimer’s dementia.


Keywords: Alzheimer's Disease, FDA, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.